Related references
Note: Only part of the references are listed.Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)
Priyanka Sharma et al.
CLINICAL CANCER RESEARCH (2021)
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update
Kimberly H. Allison et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
Yuqin Ding et al.
PLOS ONE (2020)
NCCN: Continuing Education
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
E. L. Mayer et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis
Jin Hong et al.
JOURNAL OF CANCER (2020)
St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
Marija Balic et al.
BREAST CARE (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators
Fanrong Zhang et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer
Dong Wang et al.
FUTURE ONCOLOGY (2019)
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
Lajos Pusztai et al.
LANCET ONCOLOGY (2019)
Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience
Salvatore Del Prete et al.
ONCOLOGY LETTERS (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
Jessa Gilda P. Pandy et al.
BMC CANCER (2019)
Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
Xinyan Li et al.
JOURNAL OF BREAST CANCER (2019)
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olga Caramelo et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2019)
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting
Teresa Gamucci et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history
Christoph Engel et al.
BMC CANCER (2018)
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Nadia Howlader et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2018)
Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes
Jana Soukupova et al.
PLOS ONE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Paul Gass et al.
BMC CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T. Fujii et al.
ANNALS OF ONCOLOGY (2017)
Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
Sven Kurbel et al.
BMC CANCER (2017)
Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature
Mattea Reinisch et al.
BREAST CARE (2016)
Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC plus /- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
W. M. Sikov et al.
CANCER RESEARCH (2016)
Coming of age: ten years of next-generation sequencing technologies
Sara Goodwin et al.
NATURE REVIEWS GENETICS (2016)
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer (vol 21, pg 150, 2016)
Emilio Alba et al.
ONCOLOGIST (2016)
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
Yi-Rong Liu et al.
BREAST CANCER RESEARCH (2016)
Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer
Patricia Cortazar et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer
Yu-Jie Wang et al.
Asian Pacific Journal of Cancer Prevention (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
Melinda L. Telli et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Fergus J. Couch et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer
Jason R. Brown et al.
LABORATORY INVESTIGATION (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Kunpeng Wu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
E. Alba et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Neoadjuvant Chemotherapy in the very young 35 years of age or younger
S. Loibl et al.
CANCER RESEARCH (2012)
High-resolution melting: Applications in genetic disorders
Tze-Kiong Er et al.
CLINICA CHIMICA ACTA (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
Eleftherios P. Mamounas et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Banu Arun et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Elizabeth Alli et al.
BMC Pharmacology & Toxicology (2011)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
Cornelia Liedtke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Intensified neoadjuvant chemotherapy in early-responding breast cancer:: Phase III randomized GeparTrio study
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer:: Phase III randomized GeparTrio trial
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Good clinical response of breast cancers to neoa uvant chemoendocrine therapy is associated with improved overall survival
SJ Cleator et al.
ANNALS OF ONCOLOGY (2005)
The role of BRCA1 in the cellular response to chemotherapy
RD Kennedy et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin
A Bhattacharyya et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
